Outcome disparities among ethnic subgroups of waldenström's macroglobulinemia: A population-based study

Sikander Ailawadhi, Adel Kardosh, Dongyun Yang, Wendy Cozen, Gaurav Patel, Mohammad A. Alamgir, Asher A Chanan Khan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Ethnic disparities in cancers are associated with variability in clinical outcomes. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of multiethnic Waldenström's macroglobulinemia (WM) patients. Methods: Adult WM patients diagnosed in 1992 or later (n = 3,175) were analyzed. Median overall survival (OS) was compared across different ethnicities stratified by year of diagnosis, registry identification, age at diagnosis, sex, and marital status. Results: African-Americans (AA) had the youngest median age at diagnosis (63 years) and Whites had the oldest (73 years) (p < 0.001). Female gender, a younger age at diagnosis, and a recent year of diagnosis were associated with an improved OS. Hispanics had the worst (5.6 years) while Whites had the best (6.8 years) median OS. A significant interaction existed between median OS, gender, and race (p = 0.007). Among males, AA had the worst (4.3 years) and Asians had the best (7.3 years) median OS. A significant interaction was also noted between median OS, age at diagnosis, and race (p = 0.033). The worst median OS was seen in Hispanics among patients aged >75 years, and in AA among those aged <65 years. Conclusions: These disparities among WM patients may be multifactorial but need to be explored systematically to better understand the disease biology and for optimal triaging of health care resources.

Original languageEnglish (US)
Pages (from-to)253-262
Number of pages10
JournalOncology (Switzerland)
Volume86
Issue number5-6
DOIs
StatePublished - 2014

Fingerprint

Waldenstrom Macroglobulinemia
African Americans
Population
Health Resources
Marital Status
Registries
Epidemiology
Delivery of Health Care
Survival
Neoplasms

Keywords

  • Disparity
  • Ethnicity
  • Surveillance Epidemiology and End Results
  • Survival
  • Waldenström's macroglobulinemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Outcome disparities among ethnic subgroups of waldenström's macroglobulinemia : A population-based study. / Ailawadhi, Sikander; Kardosh, Adel; Yang, Dongyun; Cozen, Wendy; Patel, Gaurav; Alamgir, Mohammad A.; Chanan Khan, Asher A.

In: Oncology (Switzerland), Vol. 86, No. 5-6, 2014, p. 253-262.

Research output: Contribution to journalArticle

Ailawadhi, Sikander ; Kardosh, Adel ; Yang, Dongyun ; Cozen, Wendy ; Patel, Gaurav ; Alamgir, Mohammad A. ; Chanan Khan, Asher A. / Outcome disparities among ethnic subgroups of waldenström's macroglobulinemia : A population-based study. In: Oncology (Switzerland). 2014 ; Vol. 86, No. 5-6. pp. 253-262.
@article{8642e562cf2e4698b0f3adf32f7bcf1b,
title = "Outcome disparities among ethnic subgroups of waldenstr{\"o}m's macroglobulinemia: A population-based study",
abstract = "Background: Ethnic disparities in cancers are associated with variability in clinical outcomes. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of multiethnic Waldenstr{\"o}m's macroglobulinemia (WM) patients. Methods: Adult WM patients diagnosed in 1992 or later (n = 3,175) were analyzed. Median overall survival (OS) was compared across different ethnicities stratified by year of diagnosis, registry identification, age at diagnosis, sex, and marital status. Results: African-Americans (AA) had the youngest median age at diagnosis (63 years) and Whites had the oldest (73 years) (p < 0.001). Female gender, a younger age at diagnosis, and a recent year of diagnosis were associated with an improved OS. Hispanics had the worst (5.6 years) while Whites had the best (6.8 years) median OS. A significant interaction existed between median OS, gender, and race (p = 0.007). Among males, AA had the worst (4.3 years) and Asians had the best (7.3 years) median OS. A significant interaction was also noted between median OS, age at diagnosis, and race (p = 0.033). The worst median OS was seen in Hispanics among patients aged >75 years, and in AA among those aged <65 years. Conclusions: These disparities among WM patients may be multifactorial but need to be explored systematically to better understand the disease biology and for optimal triaging of health care resources.",
keywords = "Disparity, Ethnicity, Surveillance Epidemiology and End Results, Survival, Waldenstr{\"o}m's macroglobulinemia",
author = "Sikander Ailawadhi and Adel Kardosh and Dongyun Yang and Wendy Cozen and Gaurav Patel and Alamgir, {Mohammad A.} and {Chanan Khan}, {Asher A}",
year = "2014",
doi = "10.1159/000360992",
language = "English (US)",
volume = "86",
pages = "253--262",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5-6",

}

TY - JOUR

T1 - Outcome disparities among ethnic subgroups of waldenström's macroglobulinemia

T2 - A population-based study

AU - Ailawadhi, Sikander

AU - Kardosh, Adel

AU - Yang, Dongyun

AU - Cozen, Wendy

AU - Patel, Gaurav

AU - Alamgir, Mohammad A.

AU - Chanan Khan, Asher A

PY - 2014

Y1 - 2014

N2 - Background: Ethnic disparities in cancers are associated with variability in clinical outcomes. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of multiethnic Waldenström's macroglobulinemia (WM) patients. Methods: Adult WM patients diagnosed in 1992 or later (n = 3,175) were analyzed. Median overall survival (OS) was compared across different ethnicities stratified by year of diagnosis, registry identification, age at diagnosis, sex, and marital status. Results: African-Americans (AA) had the youngest median age at diagnosis (63 years) and Whites had the oldest (73 years) (p < 0.001). Female gender, a younger age at diagnosis, and a recent year of diagnosis were associated with an improved OS. Hispanics had the worst (5.6 years) while Whites had the best (6.8 years) median OS. A significant interaction existed between median OS, gender, and race (p = 0.007). Among males, AA had the worst (4.3 years) and Asians had the best (7.3 years) median OS. A significant interaction was also noted between median OS, age at diagnosis, and race (p = 0.033). The worst median OS was seen in Hispanics among patients aged >75 years, and in AA among those aged <65 years. Conclusions: These disparities among WM patients may be multifactorial but need to be explored systematically to better understand the disease biology and for optimal triaging of health care resources.

AB - Background: Ethnic disparities in cancers are associated with variability in clinical outcomes. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of multiethnic Waldenström's macroglobulinemia (WM) patients. Methods: Adult WM patients diagnosed in 1992 or later (n = 3,175) were analyzed. Median overall survival (OS) was compared across different ethnicities stratified by year of diagnosis, registry identification, age at diagnosis, sex, and marital status. Results: African-Americans (AA) had the youngest median age at diagnosis (63 years) and Whites had the oldest (73 years) (p < 0.001). Female gender, a younger age at diagnosis, and a recent year of diagnosis were associated with an improved OS. Hispanics had the worst (5.6 years) while Whites had the best (6.8 years) median OS. A significant interaction existed between median OS, gender, and race (p = 0.007). Among males, AA had the worst (4.3 years) and Asians had the best (7.3 years) median OS. A significant interaction was also noted between median OS, age at diagnosis, and race (p = 0.033). The worst median OS was seen in Hispanics among patients aged >75 years, and in AA among those aged <65 years. Conclusions: These disparities among WM patients may be multifactorial but need to be explored systematically to better understand the disease biology and for optimal triaging of health care resources.

KW - Disparity

KW - Ethnicity

KW - Surveillance Epidemiology and End Results

KW - Survival

KW - Waldenström's macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84901728691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901728691&partnerID=8YFLogxK

U2 - 10.1159/000360992

DO - 10.1159/000360992

M3 - Article

C2 - 24902770

AN - SCOPUS:84901728691

VL - 86

SP - 253

EP - 262

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5-6

ER -